Citigroup Inc Avita Medical, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Avita Medical, Inc. stock. As of the latest transaction made, Citigroup Inc holds 18,445 shares of RCEL stock, worth $211,748. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,445

Previous 6,875 168.29%

Holding current value

$211,748

Previous $54,000 264.81%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$7.72 - $10.87 $89,320 - $125,765	11,570 Added 168.29%	18,445 $197,000
Q2 2024 Aug 12, 2024	SELL	$7.92 - $15.55 $317,679 - $623,726	-40,111 Reduced 85.37%	6,875 $54,000
Q1 2024 May 10, 2024	BUY	$12.56 - $18.31 $545,455 - $795,166	43,428 Added 1220.57%	46,986 $753,000
Q4 2023 Feb 09, 2024	BUY	$9.29 - $14.57 $32,914 - $51,621	3,543 Added 23620.0%	3,558 $48,000
Q3 2023 Nov 09, 2023	SELL	$13.84 - $20.79 $103,412 - $155,342	-7,472 Reduced 99.8%	15 $0
Q2 2023 Aug 10, 2023	SELL	$10.7 - $17.48 $349,451 - $570,879	-32,659 Reduced 81.35%	7,487 $127,000
Q1 2023 May 11, 2023	BUY	$6.45 - $14.48 $122,982 - $276,090	19,067 Added 90.45%	40,146 $560,000
Q4 2022 Feb 09, 2023	BUY	$4.53 - $7.55 $95,487 - $159,146	21,079 New	21,079 $139,000
Q2 2022 Aug 10, 2022	SELL	$4.6 - $8.82 $2,304 - $4,418	-501 Reduced 57.32%	373 $2,000
Q1 2022 May 12, 2022	SELL	$6.96 - $12.15 $223,903 - $390,865	-32,170 Reduced 97.36%	874 $7,000
Q4 2021 Feb 10, 2022	BUY	$11.72 - $19.66 $209,401 - $351,265	17,867 Added 117.72%	33,044 $396,000
Q3 2021 Nov 10, 2021	BUY	$16.73 - $20.9 $253,911 - $317,199	15,177 New	15,177 $269,000

Others Institutions Holding RCEL

# of Institutions

Shares Held

5.96M

Call Options Held

35.5K

Put Options Held

38K

View Full List

About AVITA Medical, Inc.

Ticker RCEL
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 25,030,900
Market Cap $287M
Description
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and prop...

More about RCEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account